05 Jul 2013

Lantus (Insuline glargine) - France

ATC: A10AE
ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
INSULINS AND ANALOGUES
INSULINS AND ANALOGUES FOR INJECTION, LONG-ACTING
Lantus

Generic Matches for Insuline glargine (1)
Optisulin

Last Updated on 05 Jul 2013 by EPG Health Media Staff.
Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page.

Lantus Indication

Traitement du diabète sucré de l’adulte, de l’adolescent et de l’enfant à partir de 2 ans.

Lantus Generic Name

Insuline glargine

Type

POM

Summary Product Characteristics (SPCs) Links
Résumé des Caractéristiques du Produit - Lantus (external site)

Free Medical Education Resources

Selected content related to Lantus (Insuline glargine)

Clinical Trials

Journals

  • Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.1
    Tang X, Yang L, He Z, Liu J.
    PLoS One. 2012;7(12):e51814. doi: 10.1371/journal.pone.0051814. Epub 2012 Dec 19.

    Aim: The role of insulin glargine as a risk factor for cancer is controversial in human studies. The aim of this meta-analysis was to evaluate the relationship between insulin glargine and cancer incidence.
    Conclusions: Results from the meta-analysis don't support the link between insulin glargine and an increased risk of cancer and the confidence in the estimates of the effects is very low. Further studies are needed to examine the relation between insulin glargine and cancer risk, especially breast cancer.
    Read full Article
     
  • Insulin glargine overdose.2
    Dogan FS, Onur OE, Altinok AD, Göneysel O.
    J Pharmacol Pharmacother. 2012 Oct;3(4):333-5. doi: 10.4103/0976-500X.103694.

    Insulin glargine is a long acting novel recombinant human insulin analogue indicated to improve glycemic control, in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. The time course of action of insulins including insulin glargine may vary between individuals and/or within the same individual. Insulin glargine is given as a 24-h dosing regimen and has no documented half-life or peak effect. Hypoglycemia is the most common adverse effect of insulin, including insulin glargine. As with all insulins, the timing of hypoglycemia may differ among various insulin formulations. We present a case of a 76-year-old male insulin-dependent diabetic patient with refractory hypoglycemia secondary to an intentional overdose of insulin glargine. We would like to highlight the necessity of prolonging IV glucose infusion, for a much longer period than expected from pharmacokinetic properties of these insulin analogues after intentional massive overdose.
    Read full Article
     
  • Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2.3
    Pierre-Eugene C, Pagesy P, Nguyen TT, Neuillé M, Tschank G, Tennagels N, Hampe C, Issad T.
    PLoS One. 2012;7(7):e41992. doi: 10.1371/journal.pone.0041992. Epub 2012 Jul 26.

    Background: In diabetic patients, the pharmacokinetics of injected human insulin does not permit optimal control of glycemia. Fast and slow acting insulin analogues have been developed, but they may have adverse properties, such as increased mitogenic or anti-apoptotic signaling. Insulin/IGF1 hybrid receptors (IR/IGF1R), present in most tissues, have been proposed to transmit biological effects close to those of IGF1R. However, the study of hybrid receptors is difficult because of the presence of IR and IGF1R homodimers. Our objective was to perform the first study on the pharmacological properties of the five marketed insulin analogues towards IR/IGF1R hybrids.
    Conclusion: Glargine, possibly acting through IR/IGF1R hybrids, displays higher potency, whereas its metabolites M1 and M2 display lower potency than insulin for the stimulation of proliferative/anti-apoptotic pathways in MCF-7 cells.
    Read full Article

News

  • Delay for basal insulin peglispro in filing at FDA for Types 1 and 2 Diabetes- Eli Lilly
    Eli Lilly and Company announced a delay in the submission of basal insulin peglispro (BIL) (LY 2605541) to regulatory agencies beyond the first quarter of 2015. The delay includes filings with the FD
     
  • Positive data from EASIE trial for Lantus (Sanofi) in patients with early Type 2 Diabetes - 10-Jun-2012
    Patients with early Type 2 Diabetes uncontrolled on metformin demonstrated superior HbA1c (glycated hemoglobin) reduction with Lantus (insulin glargine [rDNA origin] injection), from Sanofi, versus sitagliptin, according to data from the EASIE trial. Notably 50% more patients on Lantus achieved HbA1c less than 7% (68 vs. 42%) and less than 6.5% (40 vs. 17%) compared to sitagliptin, indicating improved glycemic control for a greater number of Lantus patients. Additionally, a statistically significant improvement in... Read full Article
     
  • Meta Analysis supports no increased risk of cancer by use of Lantus (Sanofi-Aventis) - 08-Dec-2011
    A new meta-analysis in relation to Lantus( insulin glargine) was presented at the World Diabetes Congress in Dubai, which added to "the wealth of evidence resulting from more than 80,000 patients enrolled in clinical trials and 38 million patient years of treatment exposure to Lantus (insulin glargine)". The figures are derived from databases as well as from clinical trials and from a case-control study in numerous countries (such as Sweden, Germany, Scotland, England and Taiwan) which assessed the risk for cancer in individuals with diabetes using different insulins. Peter Boyle, the study's lead investigator and president of the International Prevention Research Institute in Lyon, France, said the meta-analysis "highlights the need to go beyond single study reports and utilise all available data"... Read full Article

Guidelines

References

  1. Tang X, Yang L, He Z, Liu J. Insulin glargine and cancer risk in patients with diabetes: a meta-analysis. PLoS One. 2012;7(12):e51814. doi: 10.1371/journal.pone.0051814. Epub 2012 Dec 19.
  2. Dogan FS, Onur OE, Altinok AD, Göneysel O. Insulin glargine overdose. J Pharmacol Pharmacother. 2012 Oct;3(4):333-5. doi: 10.4103/0976-500X.103694.
  3. Pierre-Eugene C, Pagesy P, Nguyen TT, Neuillé M, Tschank G, Tennagels N, Hampe C, Issad T. Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2. PLoS One. 2012;7(7):e41992. doi: 10.1371/journal.pone.0041992. Epub 2012 Jul 26.

Lantus Marketing Information

Lantus Generic Name
Insuline glargine
Marketing Company
Sanofi-Aventis Deutschland GmbH
Drug Type
POM
Date of Issue, Marketing Authority

09/06/2000

Médicaments utilisés en Endocrinologie et Diabéte

Back to top